Fredag 13 Juni | 13:50:53 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2025-11-28 06:00 Kvartalsrapport 2026-Q2
2025-09-11 N/A Årsstämma
2025-06-11 - Bokslutskommuniké 2025
2024-12-02 - Kvartalsrapport 2025-Q2
2024-09-20 - Årsstämma
2024-08-13 - X-dag ordinarie utdelning H100 0.00 SEK
2024-06-11 - Bokslutskommuniké 2024
2024-01-30 - Extra Bolagsstämma 2024
2023-11-30 - Kvartalsrapport 2024-Q2
2023-09-14 - X-dag ordinarie utdelning H100 0.00 SEK
2023-09-13 - Årsstämma
2023-07-31 - Bokslutskommuniké 2023
2023-07-20 - X-dag ordinarie utdelning H100 0.00 SEK
2023-06-30 - Bokslutskommuniké 2023
2022-11-30 - Kvartalsrapport 2023-Q2
2022-07-12 - X-dag ordinarie utdelning H100 0.00 SEK
2022-07-11 - Årsstämma
2022-05-16 - Bokslutskommuniké 2022
2021-11-29 - Kvartalsrapport 2022-Q2
2021-07-07 - Årsstämma
2021-06-30 - X-dag ordinarie utdelning H100 0.00 SEK
2021-05-31 - Bokslutskommuniké 2021
2021-01-20 - Extra Bolagsstämma 2021
2020-11-23 - Kvartalsrapport 2021-Q2
2020-06-30 - X-dag ordinarie utdelning H100 0.00 SEK
2020-06-29 - Årsstämma
2020-05-22 - Bokslutskommuniké 2020

Beskrivning

LandSverige
ListaNordic SME Sweden
SektorFinans
IndustriInvesteringar
H100 Group är ett hälsoteknikbolag verksamt inom hälso- och livslängdsbranschen. Bolagets affärsidé är att stödja leverantörer av hälso- och livsstilstjänster genom AI-driven automation, digitala tillväxtverktyg och integrerade plattformslösningar. Bolaget följer en tillväxtstrategi fokuserad på att bygga ett ekosystem där AI-integration ökar effektiviteten och utökar tjänsteutbudet. H100 Group har sitt huvudkontor i Stockholm.
2025-06-12 14:29:00

H100 Group AB (publ) (“H100 Group” or the “Company”) has today received notification from Adam Back and Eagles Rising AB that they will exercise their right to invest in Tranche 2, 3 and 4 under the Company’s convertible loan framework, as announced on 3 June and 9 June 2025.

Simultaneously, the Company has received notices from both investors requesting that the full loan amounts under Tranches 1, 2, 3 and 4 shall be converted into shares in the Company in accordance with the terms in the investment and loan agreements. The agreed conversion prices are SEK 1.75 per share for Tranche 1, SEK 2.28 for Tranche 2, SEK 2.96 for Tranche 3, and SEK 3.84 for Tranche 4.

Under these terms, Adam Back has been allocated SEK 15.5 million in Tranche 1 and will be allocated SEK 15.75 million in Tranche 2, SEK 23.625 million in Tranche 3, and SEK 35.437 million in Tranche 4, amounting to a total loan contribution of approximately SEK 90.3 million. Eagles Rising AB has been allocated SEK 5.775 million in Tranche 1 and will be allocated SEK 11.025 million in Tranche 2, SEK 16.537 million in Tranche 3, and SEK 24.806 million in Tranche 4, for a total of approximately SEK 58.1 million. This implies a further capital commitment to the Company of SEK 127.1 million in addition to the SEK 101 million as announced yesterday.

Additionally, the Company has received a conversion notice from Adam Back regarding the SEK 13.5 million convertible loan announced on 25 May 2025.

The Board of Directors intends to resolve on the necessary share issues in order to effectuate the conversion, by virtue of the authorization granted by the Extraordinary General Meeting on 7 March 2025, as soon as possible. A separate press release will be issued upon resolution.

THIS PRESS RELEASE MAY NOT BE RELEASED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, CANADA, HONG KONG, BELARUS, RUSSIA OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLISHING OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTATION OR OTHER MEASURES IN ADDITION TO THOSE REQUIRED BY SWEDISH LAW. SEE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE.